Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
3
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
8
Teen smoking, drinking decline, while mental health, dietary habits worsen
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
North Korean leader ‘convinced’ dialogue won’t change US hostility
LG Chem looks to begin final stage of clinical trials for gout drug with FDA
By Kan Hyeong-wooPublished : Aug. 1, 2022 - 15:11
LG Chem has applied for phase 3 clinical trials of its gout treatment candidate Tigulixostat with the US Food and Drug Administration, the South Korean company said Monday.
If the application gets the go-ahead sign from the FDA, it will mark the first time for LG Chem to carry out phase 3 clinical trials of its self-developed new drug candidate globally including in the US, according to the company. Gout is a painful form of arthritis that is characterized by sudden, severe attacks of pain, swelling, redness and tenderness in one or more joints, most often in the big toe. It is caused by an excessive level of uric acid in the blood.
Tigulixostat is an orally administered drug that can inhibit xanthine oxidase, which produces uric acid in the blood.
The testing will be carried out in the form of placebo controlled trials in 350 adult gout patients in the US and other countries over the course of six months, according to the company.
LG Chem’s previous phase 2 clinical trials under FDA supervision confirmed that Tigulixostat demonstrated strong effects in lowering the level of uric acid in the blood along with a safety level that was on par with the placebo controlled group.
LG Chem said the goal is to obtain the FDA’s product approval in 2027 and begin the drug’s commercialization for the global market by 2028.
The company also plans to apply for a comparison trial with Alopurinol, an existing gout treatment, as it looks to prove Tigulixostat’s differentiated efficacy and safety for long-term use.
According to market tracker Coherent Market Insights, the gout treatment market is expected to reach $43 billion by 2027 from $26 billion in 2019. The number of gout patients across the world is estimated at 35 million with the US and China approximately accounting for 10 million and 14 million, respectively.
“Tigulixostat’s global phase 3 clinical trials will serve as a catalyst that improves LG Chem’s capabilities of testing new drugs, obtaining approvals, and producing and selling drugs,” said Son Jee-woong, president of Life Sciences Co. at LG Chem, in a statement.
“We will set up a new turning point for the gout treatment market through the preparations of clinical trial strategies that can secure global competitiveness as well as gearing up for preemptive commercialization.”
If the application gets the go-ahead sign from the FDA, it will mark the first time for LG Chem to carry out phase 3 clinical trials of its self-developed new drug candidate globally including in the US, according to the company. Gout is a painful form of arthritis that is characterized by sudden, severe attacks of pain, swelling, redness and tenderness in one or more joints, most often in the big toe. It is caused by an excessive level of uric acid in the blood.
Tigulixostat is an orally administered drug that can inhibit xanthine oxidase, which produces uric acid in the blood.
The testing will be carried out in the form of placebo controlled trials in 350 adult gout patients in the US and other countries over the course of six months, according to the company.
LG Chem’s previous phase 2 clinical trials under FDA supervision confirmed that Tigulixostat demonstrated strong effects in lowering the level of uric acid in the blood along with a safety level that was on par with the placebo controlled group.
LG Chem said the goal is to obtain the FDA’s product approval in 2027 and begin the drug’s commercialization for the global market by 2028.
The company also plans to apply for a comparison trial with Alopurinol, an existing gout treatment, as it looks to prove Tigulixostat’s differentiated efficacy and safety for long-term use.
According to market tracker Coherent Market Insights, the gout treatment market is expected to reach $43 billion by 2027 from $26 billion in 2019. The number of gout patients across the world is estimated at 35 million with the US and China approximately accounting for 10 million and 14 million, respectively.
“Tigulixostat’s global phase 3 clinical trials will serve as a catalyst that improves LG Chem’s capabilities of testing new drugs, obtaining approvals, and producing and selling drugs,” said Son Jee-woong, president of Life Sciences Co. at LG Chem, in a statement.
“We will set up a new turning point for the gout treatment market through the preparations of clinical trial strategies that can secure global competitiveness as well as gearing up for preemptive commercialization.”
